Systemic Scleroderma Treatment Market, Global Outlook and Forecast 2022-2028

January 2022 | 66 pages | ID: S582C94EB5A6EN
Market Monitor Global

Abstracts

Systemic scleroderma is a systemic autoimmune disease characterized by localized or diffuse skin thickening and fibrosis. The lesions were characterized by fibrous hyperplasia and onion like changes in blood vessels, which eventually led to skin sclerosis and vascular ischemia. This disease is characterized by localized or diffuse skin thickening and fibrosis. In addition to skin involvement, it can also affect visceral organs (such as heart, lung and digestive tract). As an autoimmune disease, it is often accompanied by autoantibodies such as antinuclear antibody, anti centromere antibody and anti ScL-70. The incidence rate of this disease is more than 4 times that of men, and children are relatively rare.

This report contains market size and forecasts of Systemic Scleroderma Treatment in Global, including the following market information:

Global Systemic Scleroderma Treatment Market Revenue, 2017-2022, 2023-2028, ($ millions)

Global top five companies in 2021 (%)

The global Systemic Scleroderma Treatment market was valued at 1604.4 million in 2021 and is projected to reach US$ 2149.7 million by 2028, at a CAGR of 4.3% during the forecast period.

The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.

Immunosuppressors Segment to Reach $ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Systemic Scleroderma Treatment include Boehringer Ingelheim International GmbH, Gilead Sciences Inc., GlaxoSmithKline plc, Novartis AG, Pfizer Inc. and Bayer AG, etc. In 2021, the global top five players have a share approximately % in terms of revenue.

MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Systemic Scleroderma Treatment companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Systemic Scleroderma Treatment Market, by Type, 2017-2022, 2023-2028 ($ millions)

Global Systemic Scleroderma Treatment Market Segment Percentages, by Type, 2021 (%)

• Immunosuppressors
• Phosphodiesterase 5 inhibitors - PHA
• Endothelin Receptor Antagonists
• Prostacyclin Analogues
• Calcium Channel Blockers
• Others

Global Systemic Scleroderma Treatment Market, by Application, 2017-2022, 2023-2028 ($ millions)

Global Systemic Scleroderma Treatment Market Segment Percentages, by Application, 2021 (%)

• Skin
• Bones and Joints
• Digestive System
• Lung
• Heart
• Kidney

Global Systemic Scleroderma Treatment Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)

Global Systemic Scleroderma Treatment Market Segment Percentages, By Region and Country, 2021 (%)

• North America
• US
• Canada
• Mexico
• Europe
• Germany
• France
• U.K.
• Italy
• Russia
• Nordic Countries
• Benelux
• Rest of Europe
• Asia
• China
• Japan
• South Korea
• Southeast Asia
• India
• Rest of Asia
• South America
• Brazil
• Argentina
• Rest of South America
• Middle East & Africa
• Turkey
• Israel
• Saudi Arabia
• UAE
• Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies Systemic Scleroderma Treatment revenues in global market, 2017-2022 (estimated), ($ millions)

Key companies Systemic Scleroderma Treatment revenues share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

• Boehringer Ingelheim International GmbH
• Gilead Sciences Inc.
• GlaxoSmithKline plc
• Novartis AG
• Pfizer Inc.
• Bayer AG

Contents

1 INTRODUCTION TO RESEARCH & ANALYSIS REPORTS

1.1 Systemic Scleroderma Treatment Market Definition
1.2 Market Segments
  1.2.1 Market by Type
  1.2.2 Market by Application
1.3 Global Systemic Scleroderma Treatment Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
  1.5.1 Research Methodology
  1.5.2 Research Process
  1.5.3 Base Year
  1.5.4 Report Assumptions & Caveats

2 GLOBAL SYSTEMIC SCLERODERMA TREATMENT OVERALL MARKET SIZE

2.1 Global Systemic Scleroderma Treatment Market Size: 2021 VS 2028
2.2 Global Systemic Scleroderma Treatment Market Size, Prospects & Forecasts: 2017-2028
2.3 Key Market Trends, Opportunity, Drivers and Restraints
  2.3.1 Market Opportunities & Trends
  2.3.2 Market Drivers
  2.3.3 Market Restraints

3 COMPANY LANDSCAPE

3.1 Top Systemic Scleroderma Treatment Players in Global Market
3.2 Top Global Systemic Scleroderma Treatment Companies Ranked by Revenue
3.3 Global Systemic Scleroderma Treatment Revenue by Companies
3.4 Top 3 and Top 5 Systemic Scleroderma Treatment Companies in Global Market, by Revenue in 2021
3.5 Global Companies Systemic Scleroderma Treatment Product Type
3.6 Tier 1, Tier 2 and Tier 3 Systemic Scleroderma Treatment Players in Global Market
  3.6.1 List of Global Tier 1 Systemic Scleroderma Treatment Companies
  3.6.2 List of Global Tier 2 and Tier 3 Systemic Scleroderma Treatment Companies

4 MARKET SIGHTS BY PRODUCT

4.1 Overview
  4.1.1 by Type - Global Systemic Scleroderma Treatment Market Size Markets, 2021 & 2028
  4.1.2 Immunosuppressors
  4.1.3 Phosphodiesterase 5 inhibitors - PHA
  4.1.4 Endothelin Receptor Antagonists
  4.1.5 Prostacyclin Analogues
  4.1.6 Calcium Channel Blockers
  4.1.7 Others
4.2 By Type - Global Systemic Scleroderma Treatment Revenue & Forecasts
  4.2.1 By Type - Global Systemic Scleroderma Treatment Revenue, 2017-2022
  4.2.2 By Type - Global Systemic Scleroderma Treatment Revenue, 2023-2028
  4.2.3 By Type - Global Systemic Scleroderma Treatment Revenue Market Share, 2017-2028

5 SIGHTS BY APPLICATION

5.1 Overview
  5.1.1 By Application - Global Systemic Scleroderma Treatment Market Size, 2021 & 2028
  5.1.2 Skin
  5.1.3 Bones and Joints
  5.1.4 Digestive System
  5.1.5 Lung
  5.1.6 Heart
  5.1.7 Kidney
5.2 By Application - Global Systemic Scleroderma Treatment Revenue & Forecasts
  5.2.1 By Application - Global Systemic Scleroderma Treatment Revenue, 2017-2022
  5.2.2 By Application - Global Systemic Scleroderma Treatment Revenue, 2023-2028
  5.2.3 By Application - Global Systemic Scleroderma Treatment Revenue Market Share, 2017-2028

6 SIGHTS BY REGION

6.1 By Region - Global Systemic Scleroderma Treatment Market Size, 2021 & 2028
6.2 By Region - Global Systemic Scleroderma Treatment Revenue & Forecasts
  6.2.1 By Region - Global Systemic Scleroderma Treatment Revenue, 2017-2022
  6.2.2 By Region - Global Systemic Scleroderma Treatment Revenue, 2023-2028
  6.2.3 By Region - Global Systemic Scleroderma Treatment Revenue Market Share, 2017-2028
6.3 North America
  6.3.1 By Country - North America Systemic Scleroderma Treatment Revenue, 2017-2028
  6.3.2 US Systemic Scleroderma Treatment Market Size, 2017-2028
  6.3.3 Canada Systemic Scleroderma Treatment Market Size, 2017-2028
  6.3.4 Mexico Systemic Scleroderma Treatment Market Size, 2017-2028
6.4 Europe
  6.4.1 By Country - Europe Systemic Scleroderma Treatment Revenue, 2017-2028
  6.4.2 Germany Systemic Scleroderma Treatment Market Size, 2017-2028
  6.4.3 France Systemic Scleroderma Treatment Market Size, 2017-2028
  6.4.4 U.K. Systemic Scleroderma Treatment Market Size, 2017-2028
  6.4.5 Italy Systemic Scleroderma Treatment Market Size, 2017-2028
  6.4.6 Russia Systemic Scleroderma Treatment Market Size, 2017-2028
  6.4.7 Nordic Countries Systemic Scleroderma Treatment Market Size, 2017-2028
  6.4.8 Benelux Systemic Scleroderma Treatment Market Size, 2017-2028
6.5 Asia
  6.5.1 By Region - Asia Systemic Scleroderma Treatment Revenue, 2017-2028
  6.5.2 China Systemic Scleroderma Treatment Market Size, 2017-2028
  6.5.3 Japan Systemic Scleroderma Treatment Market Size, 2017-2028
  6.5.4 South Korea Systemic Scleroderma Treatment Market Size, 2017-2028
  6.5.5 Southeast Asia Systemic Scleroderma Treatment Market Size, 2017-2028
  6.5.6 India Systemic Scleroderma Treatment Market Size, 2017-2028
6.6 South America
  6.6.1 By Country - South America Systemic Scleroderma Treatment Revenue, 2017-2028
  6.6.2 Brazil Systemic Scleroderma Treatment Market Size, 2017-2028
  6.6.3 Argentina Systemic Scleroderma Treatment Market Size, 2017-2028
6.7 Middle East & Africa
  6.7.1 By Country - Middle East & Africa Systemic Scleroderma Treatment Revenue, 2017-2028
  6.7.2 Turkey Systemic Scleroderma Treatment Market Size, 2017-2028
  6.7.3 Israel Systemic Scleroderma Treatment Market Size, 2017-2028
  6.7.4 Saudi Arabia Systemic Scleroderma Treatment Market Size, 2017-2028
  6.7.5 UAE Systemic Scleroderma Treatment Market Size, 2017-2028

7 PLAYERS PROFILES

7.1 Boehringer Ingelheim International GmbH
  7.1.1 Boehringer Ingelheim International GmbH Corporate Summary
  7.1.2 Boehringer Ingelheim International GmbH Business Overview
  7.1.3 Boehringer Ingelheim International GmbH Systemic Scleroderma Treatment Major Product Offerings
  7.1.4 Boehringer Ingelheim International GmbH Systemic Scleroderma Treatment Revenue in Global Market (2017-2022)
  7.1.5 Boehringer Ingelheim International GmbH Key News
7.2 Gilead Sciences Inc.
  7.2.1 Gilead Sciences Inc. Corporate Summary
  7.2.2 Gilead Sciences Inc. Business Overview
  7.2.3 Gilead Sciences Inc. Systemic Scleroderma Treatment Major Product Offerings
  7.2.4 Gilead Sciences Inc. Systemic Scleroderma Treatment Revenue in Global Market (2017-2022)
  7.2.5 Gilead Sciences Inc. Key News
7.3 GlaxoSmithKline plc
  7.3.1 GlaxoSmithKline plc Corporate Summary
  7.3.2 GlaxoSmithKline plc Business Overview
  7.3.3 GlaxoSmithKline plc Systemic Scleroderma Treatment Major Product Offerings
  7.3.4 GlaxoSmithKline plc Systemic Scleroderma Treatment Revenue in Global Market (2017-2022)
  7.3.5 GlaxoSmithKline plc Key News
7.4 Novartis AG
  7.4.1 Novartis AG Corporate Summary
  7.4.2 Novartis AG Business Overview
  7.4.3 Novartis AG Systemic Scleroderma Treatment Major Product Offerings
  7.4.4 Novartis AG Systemic Scleroderma Treatment Revenue in Global Market (2017-2022)
  7.4.5 Novartis AG Key News
7.5 Pfizer Inc.
  7.5.1 Pfizer Inc. Corporate Summary
  7.5.2 Pfizer Inc. Business Overview
  7.5.3 Pfizer Inc. Systemic Scleroderma Treatment Major Product Offerings
  7.5.4 Pfizer Inc. Systemic Scleroderma Treatment Revenue in Global Market (2017-2022)
  7.5.5 Pfizer Inc. Key News
7.6 Bayer AG
  7.6.1 Bayer AG Corporate Summary
  7.6.2 Bayer AG Business Overview
  7.6.3 Bayer AG Systemic Scleroderma Treatment Major Product Offerings
  7.6.4 Bayer AG Systemic Scleroderma Treatment Revenue in Global Market (2017-2022)
  7.6.5 Bayer AG Key News

8 CONCLUSION

9 APPENDIX

9.1 Note
9.2 Examples of Clients
9.3 Disclaimer

List Of Tables

LIST OF TABLES

Table 1. Systemic Scleroderma Treatment Market Opportunities & Trends in Global Market
Table 2. Systemic Scleroderma Treatment Market Drivers in Global Market
Table 3. Systemic Scleroderma Treatment Market Restraints in Global Market
Table 4. Key Players of Systemic Scleroderma Treatment in Global Market
Table 5. Top Systemic Scleroderma Treatment Players in Global Market, Ranking by Revenue (2021)
Table 6. Global Systemic Scleroderma Treatment Revenue by Companies, (US$, Mn), 2017-2022
Table 7. Global Systemic Scleroderma Treatment Revenue Share by Companies, 2017-2022
Table 8. Global Companies Systemic Scleroderma Treatment Product Type
Table 9. List of Global Tier 1 Systemic Scleroderma Treatment Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Systemic Scleroderma Treatment Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 11. By Type – Global Systemic Scleroderma Treatment Revenue, (US$, Mn), 2021 & 2028
Table 12. By Type - Systemic Scleroderma Treatment Revenue in Global (US$, Mn), 2017-2022
Table 13. By Type - Systemic Scleroderma Treatment Revenue in Global (US$, Mn), 2023-2028
Table 14. By Application – Global Systemic Scleroderma Treatment Revenue, (US$, Mn), 2021 & 2028
Table 15. By Application - Systemic Scleroderma Treatment Revenue in Global (US$, Mn), 2017-2022
Table 16. By Application - Systemic Scleroderma Treatment Revenue in Global (US$, Mn), 2023-2028
Table 17. By Region – Global Systemic Scleroderma Treatment Revenue, (US$, Mn), 2021 & 2028
Table 18. By Region - Global Systemic Scleroderma Treatment Revenue (US$, Mn), 2017-2022
Table 19. By Region - Global Systemic Scleroderma Treatment Revenue (US$, Mn), 2023-2028
Table 20. By Country - North America Systemic Scleroderma Treatment Revenue, (US$, Mn), 2017-2022
Table 21. By Country - North America Systemic Scleroderma Treatment Revenue, (US$, Mn), 2023-2028
Table 22. By Country - Europe Systemic Scleroderma Treatment Revenue, (US$, Mn), 2017-2022
Table 23. By Country - Europe Systemic Scleroderma Treatment Revenue, (US$, Mn), 2023-2028
Table 24. By Region - Asia Systemic Scleroderma Treatment Revenue, (US$, Mn), 2017-2022
Table 25. By Region - Asia Systemic Scleroderma Treatment Revenue, (US$, Mn), 2023-2028
Table 26. By Country - South America Systemic Scleroderma Treatment Revenue, (US$, Mn), 2017-2022
Table 27. By Country - South America Systemic Scleroderma Treatment Revenue, (US$, Mn), 2023-2028
Table 28. By Country - Middle East & Africa Systemic Scleroderma Treatment Revenue, (US$, Mn), 2017-2022
Table 29. By Country - Middle East & Africa Systemic Scleroderma Treatment Revenue, (US$, Mn), 2023-2028
Table 30. Boehringer Ingelheim International GmbH Corporate Summary
Table 31. Boehringer Ingelheim International GmbH Systemic Scleroderma Treatment Product Offerings
Table 32. Boehringer Ingelheim International GmbH Systemic Scleroderma Treatment Revenue (US$, Mn), (2017-2022)
Table 33. Gilead Sciences Inc. Corporate Summary
Table 34. Gilead Sciences Inc. Systemic Scleroderma Treatment Product Offerings
Table 35. Gilead Sciences Inc. Systemic Scleroderma Treatment Revenue (US$, Mn), (2017-2022)
Table 36. GlaxoSmithKline plc Corporate Summary
Table 37. GlaxoSmithKline plc Systemic Scleroderma Treatment Product Offerings
Table 38. GlaxoSmithKline plc Systemic Scleroderma Treatment Revenue (US$, Mn), (2017-2022)
Table 39. Novartis AG Corporate Summary
Table 40. Novartis AG Systemic Scleroderma Treatment Product Offerings
Table 41. Novartis AG Systemic Scleroderma Treatment Revenue (US$, Mn), (2017-2022)
Table 42. Pfizer Inc. Corporate Summary
Table 43. Pfizer Inc. Systemic Scleroderma Treatment Product Offerings
Table 44. Pfizer Inc. Systemic Scleroderma Treatment Revenue (US$, Mn), (2017-2022)
Table 45. Bayer AG Corporate Summary
Table 46. Bayer AG Systemic Scleroderma Treatment Product Offerings
Table 47. Bayer AG Systemic Scleroderma Treatment Revenue (US$, Mn), (2017-2022)

List Of Figures

LIST OF FIGURES

Figure 1. Systemic Scleroderma Treatment Segment by Type in 2021
Figure 2. Systemic Scleroderma Treatment Segment by Application in 2021
Figure 3. Global Systemic Scleroderma Treatment Market Overview: 2021
Figure 4. Key Caveats
Figure 5. Global Systemic Scleroderma Treatment Market Size: 2021 VS 2028 (US$, Mn)
Figure 6. Global Systemic Scleroderma Treatment Revenue, 2017-2028 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Systemic Scleroderma Treatment Revenue in 2021
Figure 8. By Type - Global Systemic Scleroderma Treatment Revenue Market Share, 2017-2028
Figure 9. By Application - Global Systemic Scleroderma Treatment Revenue Market Share, 2017-2028
Figure 10. By Region - Global Systemic Scleroderma Treatment Revenue Market Share, 2017-2028
Figure 11. By Country - North America Systemic Scleroderma Treatment Revenue Market Share, 2017-2028
Figure 12. US Systemic Scleroderma Treatment Revenue, (US$, Mn), 2017-2028
Figure 13. Canada Systemic Scleroderma Treatment Revenue, (US$, Mn), 2017-2028
Figure 14. Mexico Systemic Scleroderma Treatment Revenue, (US$, Mn), 2017-2028
Figure 15. By Country - Europe Systemic Scleroderma Treatment Revenue Market Share, 2017-2028
Figure 16. Germany Systemic Scleroderma Treatment Revenue, (US$, Mn), 2017-2028
Figure 17. France Systemic Scleroderma Treatment Revenue, (US$, Mn), 2017-2028
Figure 18. U.K. Systemic Scleroderma Treatment Revenue, (US$, Mn), 2017-2028
Figure 19. Italy Systemic Scleroderma Treatment Revenue, (US$, Mn), 2017-2028
Figure 20. Russia Systemic Scleroderma Treatment Revenue, (US$, Mn), 2017-2028
Figure 21. Nordic Countries Systemic Scleroderma Treatment Revenue, (US$, Mn), 2017-2028
Figure 22. Benelux Systemic Scleroderma Treatment Revenue, (US$, Mn), 2017-2028
Figure 23. By Region - Asia Systemic Scleroderma Treatment Revenue Market Share, 2017-2028
Figure 24. China Systemic Scleroderma Treatment Revenue, (US$, Mn), 2017-2028
Figure 25. Japan Systemic Scleroderma Treatment Revenue, (US$, Mn), 2017-2028
Figure 26. South Korea Systemic Scleroderma Treatment Revenue, (US$, Mn), 2017-2028
Figure 27. Southeast Asia Systemic Scleroderma Treatment Revenue, (US$, Mn), 2017-2028
Figure 28. India Systemic Scleroderma Treatment Revenue, (US$, Mn), 2017-2028
Figure 29. By Country - South America Systemic Scleroderma Treatment Revenue Market Share, 2017-2028
Figure 30. Brazil Systemic Scleroderma Treatment Revenue, (US$, Mn), 2017-2028
Figure 31. Argentina Systemic Scleroderma Treatment Revenue, (US$, Mn), 2017-2028
Figure 32. By Country - Middle East & Africa Systemic Scleroderma Treatment Revenue Market Share, 2017-2028
Figure 33. Turkey Systemic Scleroderma Treatment Revenue, (US$, Mn), 2017-2028
Figure 34. Israel Systemic Scleroderma Treatment Revenue, (US$, Mn), 2017-2028
Figure 35. Saudi Arabia Systemic Scleroderma Treatment Revenue, (US$, Mn), 2017-2028
Figure 36. UAE Systemic Scleroderma Treatment Revenue, (US$, Mn), 2017-2028
Figure 37. Boehringer Ingelheim International GmbH Systemic Scleroderma Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 38. Gilead Sciences Inc. Systemic Scleroderma Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 39. GlaxoSmithKline plc Systemic Scleroderma Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 40. Novartis AG Systemic Scleroderma Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 41. Pfizer Inc. Systemic Scleroderma Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 42. Bayer AG Systemic Scleroderma Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)